VANCOUVER, BC, TORONTO and LONDON, May 23, 2023 /PRNewswire/ – BZAM Ltd. (the “Company” or “BZAM“) (CSE: BZAM) (US-OTC: BZAMF), is pleased to announce that its subsidiary, The Green Organic Dutchman Ltd. (collectively the “Company”) has entered into a strategic distribution agreement with 4C LABS Ltd. (“4C LABS”), a London, UK based import & distribution company focused on the medical cannabis space. The Company and 4C LABS expect to commercialize medical cannabis products under The Green Organic Dutchman brand in the UK beginning in Q4 2023.

Pursuant to the agreement, signed on April 29, 2023, the Company will supply 4C LABS with approximately 600KG of flower annually for the next two years.

The Company is a premier, certified organic grower of medical cannabis in living soil. The Company recently received EU GMP certification for its greenhouse facility located in Ancaster, Ontario, Canada. This certification permits the Company to export certain medical cannabis products to numerous global markets, including the UK.

4C LABS believes that there is strong demand for quality, organic Canadian cannabis products in the UK’s burgeoning medical cannabis market. The team at 4C LABS expects the market to expand over the next five years, mirroring previously legalized medical markets elsewhere, and expects this new agreement will enable them to establish a dominant position in the UK medical cannabis market.

Matt Milich, BZAM’s CEO, stated: “We are proud to announce this agreement with 4C LABS to bring our exceptional product to the UK market. Executing on our recent EU GMP Certification is a key priority and we are excited to be able to partner with local experts like 4C LABS.”

Greg Dobbin, 4C LABS CEO, stated: “We are extremely pleased to be able to offer The Green Organic Dutchman products to our UK patients. BZAM is a world class company which operates a truly innovative facility where Canada’s best growers and unique genetics come together. From feeding certain plants maple syrup to creating community gardens at their grow facility, the BZAM team takes medical cannabis to the next level.”

About BZAM Ltd.

BZAM Ltd. (CSE: BZAM) (OTC: BZAMF) is a leading Canadian cannabis producer with a focus on branded consumer goods, innovation, quality, consistency, integrity, sustainability and transparency. The BZAM family includes core brands BZAM, TGOD, ness, Highly Dutch Organic, TABLE TOP, and partner brands Dunn Cannabis, FRESH and Wyld. BZAM operates facilities in BC, Alberta, Ontario and Quebec, as well as retail stores in Winnipeg, Manitoba and Regina, Saskatchewan.

BZAM’s Common Shares and certain warrants issued under the indentures dated June 12, 2020, October 23, 2020, and December 10, 2020, currently trade on the Canadian Securities Exchange (the “CSE”) under the symbol “BZAM”. BZAM’s Common Shares trade in the U.S. on the OTCQX under the symbol “BZAMF”. For more information, please visit www.bzam.com

About 4C LABS Ltd.

4C LABS Ltd. is a privately held UK medical cannabis company focusing on providing patients with world class medical cannabis products at an affordable price. 4C LABS has import and distribution licenses in the UK and a wide network of pharmacies in the UK & Channel Islands. 4C LABS carries a full product line of medical cannabis from a selected network of trusted international cultivation partners. For more information, please visit www.4clabs.co

Cautionary Statements

This news release includes statements containing certain “forward–looking information” within the meaning of applicable securities law (“forward–looking statements”). Forward looking statements in this release include, but are not limited to, statements about future production quantity and timing, statements about the offering of any particular products by the Company and statements regarding the future performance of the Company, statements about funding availability, statements about growth and delivery of products, and statements about the level of demand for BZAM’s products, statements relating to the creation and timing of any revenue in the UK, and statements about the future size of any international markets. Forward–looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “should”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward–looking statements throughout this news release, such as assumptions that the Company’s financial trajectory will continue, the Company not having any issues with regulators, cultivation patterns at the Company’s facilities continuing and there not being significant disruptions in cultivation such as disease or shortages in resources, the Company being insulated from supply chain issues and inflation affecting the global economy, the Company being able to access the capital markets and existing lenders for necessary funding, when necessary, demand for the Company’s products continuing as expected and based on past trends. Forward–looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties (including market conditions) and other factors that could cause actual events or results to differ materially from those projected in the forward–looking statements, including those risk factors described in Management’s Discussion and Analysis and the Company’s most recent Annual Information Form filed with Canadian securities regulators and available on the Company’s issuer profile on SEDAR at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking information or forward-looking statements in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information and forward-looking statements included in this news release are made as of the date of this news release. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward–looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Neither the CSE nor the CSE’s Regulation Services Provider (as that term is defined in the policies of CSE) accept responsibility for the adequacy or accuracy of this release.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

BURLINGTON, Ontario, December 09, 2021–(BUSINESS WIRE)–Rapid Dose Therapeutics Corp. (“RDT” or the “Company“) (CSE: DOSE), a Canadian biotechnology company revolutionizing drug delivery through innovation, entered into an agreement on Friday, November 26, 2021 with Oakland Health Limited (“Oakland Health” operating as “RD Therapeutics”) to supply QuickStrip products to the United Kingdom and the European Union.

“This strategic partnership supports our business plan of rapid global expansion, bringing our novel QuickStrip technology and nutraceutical products into the United Kingdom, with further expansion plans throughout the European Union,” said Mark Upsdell, CEO Rapid Dose Therapeutics. “It is as a result of our strategic partnerships with leading organizations such as RD Therapeutics that we will achieve broader awareness of our novel delivery technology, as it becomes more widely used, including as an oral delivery system for vaccines.”

RD Therapeutics is well positioned to maximize sales in these geographies, with their strong relationships throughout the UK and EU in both pharmacy and retail chains, critical for broad education and uptake of QuickStrip products in these markets.

“We are very pleased to have been selected by Rapid Dose Therapeutics to bring their innovative products to the UK and EU marketplaces,” said Ailene Thiel, CEO, RD Therapeutics. “This novel technology will be welcomed in these markets as a truly innovative delivery mechanism, initially for nutraceuticals, with expansion into pharmaceuticals and vaccines to follow. We are looking forward to operating as RDT’s UK and European supply partners and will support the marketing and sales of these outstanding products with scientific rigour and our in-depth knowledge of the markets we serve.”

RD Therapeutics placed an initial product order on Friday, December 3, 2021, including RDT and white label branded products in the lifestyle, health and wellness sectors, for delivery in Q1 2022.

About Rapid Dose Therapeutics Corp.

Rapid Dose Therapeutics is a Canadian biotechnology company revolutionizing drug delivery through innovation. The Company’s flagship product QuickStrip is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients, including nutraceuticals, pharmaceuticals and vaccines, that are delivered quickly into the bloodstream, resulting in rapid onset of the active ingredient.
www.rapid-dose.com

About Oakland Health Limited Operating as “RD Therapeutics”

Driven by science, technology and clinical evidence, RD Therapeutics was formed by a multidisciplinary team of industry experts with global experience across the technology, pharmaceutical and nutraceutical industries. The company’s professional trajectory has taught it the importance of being at the forefront of research and technological advances in product development to bring to market a unique range of products that will help to create a society in which health and wellness as a way of life is within the reach of all.
www.rdtherapeutics.com

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS:

Certain information in this news release may contain forward-looking information within the meaning of applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend”, “will”, “could”, “are planned to”, “are expected to” or the negative of these terms and similar expressions. Statements containing forward-looking information, including, without limitation, in respect of the delivery of equipment and products using the QuickStrip product delivery method, the generation of recurring revenues, as at the date of this news release, the plans, estimates, forecasts, projections, expectations or beliefs of RDT management as to future events or results and are believed to be reasonable based on information currently available to RDT management. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; termination of WLM agreements; future legislative and regulatory developments involving cannabis; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the cannabis industry in Canada generally, income tax and regulatory matters; the ability to implement its business strategies; competition; currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing list is not exhaustive. There can be no assurance that statements of forward-looking information, although considered reasonable by RDT management at the time of preparation, will prove to be accurate as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. Actual results and future events could differ materially from those anticipated in such forward-looking statements. Readers should not place undue reliance on forward-looking statements. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211209005662/en/

Contacts

Investor:
Mark Upsdell, CEO
[email protected]
416-477-1052

Media:
Kim Robinson
[email protected]
905-330-4055

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

• Zerenia Clinics UK is a specialist medical cannabis clinic in London and another strategic approach by Khiron to improve access to medical cannabis for patients in the UK
• Hybrid clinic model: Zerenia Clinics UK is a digital clinic (www.zereniaclinic.co.uk) and will also offer in-person appointments with medical cannabis specialist practitioners
• The new Zerenia location in UK brings Khiron’s total global clinic count to 15 throughout Latin America and Europe and underscores its proven patient-centered approach
• The implementation of the Company’s clinic strategy will strengthen Khiron’s European sales, which now account for 30% of the Company’s total medical cannabis revenues for Q3 2021

TORONTO, Nov. 3, 2021 /CNW/ – Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN) (OTCQX: KHRNF)(Frankfurt:A2JMZC), a vertically integrated medical cannabis leader with core operations in Latin America and Europe, is pleased to announce the opening of Zerenia Clinics UK in London as its first International Zerenia clinic in Europe. This collectively brings the Company’s total clinic count to 15 globally. Both virtual and in-person appointments can be made via the website www.zereniaclinic.co.uk.

Khiron in the United Kingdom
The company is pursuing a consistent approach to improve patient access to medical cannabis and to develop the market for medical cannabis treatments in the UK. The opening of Zerenia Clinics UK by an expert team is another step in this direction that expands Khiron’s presence in Europe, where medical cannabis sales have grown more than 6x since Q1 2021. Even though Germany will continue to dominate the European market for medical cannabis until at least 2024, industry consultants Prohibition Partners expect the UK medical cannabis market to show the most significant growth of any country in Europe by 2025.

Zerenia Clinics UK will build upon Khiron’s presence in the UK which started in 2019 when Khiron became a founding member and also the exclusive Latin American supplier for Project Twenty21 which offers a subsidized pricing model for patients in the program to help address barriers to access in the UK market. The Company continues to focus on medical training for healthcare professionals after receiving full Continuing Professional Development (“CPD”) accreditation for its digital educational platform, Khiron Academy, and brings its proprietary clinical data generated in LatAm to the UK.

The Zerenia Clinic model
In the initial phase of operations, Zerenia Clinics UK will focus on pain management and will then expand its therapeutic portfolio to other areas such as mental health, women´s health, neurology and oncology. Though prominently located in London’s famous Chelsea district, Zerenia Clinics UK will initially focus on supporting patients digitally (or via video-consultations) to enable streamlined access to patients across the UK, many of whom suffer from debilitating conditions. Zerenia Clinics UK follows the high-quality standards of personalised cannabinoid-based therapies and pursues precision-based medicine with the central goal to improve patient access to cannabinoid-based therapies.

In LatAm, the proven clinic model Zerenia is a patient-centered integrated care model combining traditional and complementary medicine with a focus on treatments with medical cannabis. The 14 Zerenia clinics in Colombia and Peru are known for their evidence-based treatments and highly professional applications with over 14,000 individual patients treated to date.

Franziska Katterbach, President Khiron Europe commented, “I am very excited about the opening of Zerenia Clinics UK in London with our very experienced local team. This is a great milestone for Khiron and will contribute significantly to the dynamics of developing a market for medical cannabis in the UK. From day one, it has been our goal to improve patient access to medical cannabis where suitable and also create evidence for the effectiveness and tolerability of medical cannabis; opening a UK cannabis clinic is just another logical step to serve patient’s and clinician’s needs.”

About Khiron Life Sciences Corp.
Khiron is a leading vertically integrated international medical cannabis company with core operations in Latin America and Europe. Leveraging wholly-owned medical health clinics and proprietary telemedicine platforms, Khiron combines a patient-oriented approach, physician education programs, scientific expertise, product innovation, and agricultural infrastructure to drive prescriptions and brand loyalty with patients worldwide. The Company has a sales presence in Colombia, Peru, Germany, UK, and Brazil and is positioned to commence sales in Mexico. The Company is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and diverse executive team and Board of Directors.

Visit Khiron online at investors.khiron.ca and on Linkedin at https://www.linkedin.com/company/khiron-life-sciences-corp/

Cautionary Notes

Forward-Looking Statements

This press release may contain certain “forward-looking information” and “forward-looking statements” within the meaning of applicable securities legislation. All information contained herein that is not historical in nature may constitute forward-looking information. Khiron undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statement has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron’s control, including the risk factors discussed in Khiron’s Annual Information Form which is available on Khiron’s SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and is made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

SOURCE Khiron Life Sciences Corp.

For further information: Investor Contact: Paola Ricardo, E: [email protected], T: +1 (647) 556-5750; Media Contact: Peter Leis, Europe Communications, E: [email protected]; Khiron Europe: Franziska Katterbach, President, E: [email protected]

Related Links

https://khiron.ca/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

NEW YORK–(BUSINESS WIRE)– Columbia Care Inc. (NEO: CCHW) (CSE: CCHW) (OTCQX: CCHWF) (FSE: 3LP) (“Columbia Care” or the “Company”) announced today the launch of its proprietary solid-fill cannabis powder capsule for medicinal use throughout the United Kingdom. This is the first solid-fill capsule of its kind available in the UK and the first dose-metered medicinal cannabis product to be manufactured in the UK. The capsules are part of Columbia Care’s trademarked Ceed medicinal product range.

The patent-pending, proprietary capsules were first developed and successfully commercialized in the United States by Columbia Care. They incorporate a portfolio of primary and secondary cannabinoids and are available in a number of formulations with various THC and CBD doses. These dosing options enable prescribing physicians to offer proven, cannabis-based medical solutions with a degree of precision previously unavailable in the UK market. When compared with other cannabinoid-based medicinal product (CBMP) formulations, this form factor has longer-lasting effects, with demonstrated success throughout the United States, by offering patients relief that lasts all night, or throughout their day. Data from Columbia Care’s proprietary IMPACT REGISTRY^TM database demonstrates that this formulation is preferred by certain demographics, such as patients over 65, increasing the potential addressable market due to the familiar and trusted medical form.

“This achievement is a testament to our team and partners who worked diligently to bring a product to market that fulfills a significant unmet patient and physician need in the UK. To be the first in any market is a reflection of our prudent capital allocation process and the culture of collaboration that permeates all aspects of our business. It also highlights the commitment to our medical heritage, research and development, and leading the industry on a global basis through innovation. We are thrilled to be among the market leaders responsible for driving the cannabis industry forward in the UK,” said Nicholas Vita, CEO, Columbia Care.

As the UK’s medical cannabis market continues to grow, this formulation has been introduced in response to physician and patient demand for more precise dosing options as well as more familiar form factors in CBMPs. Prior to the launch of Columbia Care’s solid-fill cannabis powder capsules, UK patients’ and physicians’ formulation options for CBMPs had been limited to cannabis flower and sublingual tinctures made with cannabis extracts. This capsule provides more ease-of-use for those with limited dexterity, and due to its bioavailability profile, has longer lasting effects – meaning patients can save money, benefit from less frequent dosing, and incorporate this efficacious treatment into their daily routine as they would any other medicine.

“Our solid-fill capsule provides numerous advantages for the patient. We believe this has the potential to truly drive normalization around cannabis use for physicians and patients alike,” said Rosemary Mazanet, M.D./Ph.D., Chief Scientific Officer, Columbia Care. “As we’ve seen with other medical cannabis programs around the world, doseable formulations, de-stigmatization and improved understanding of therapeutic cannabinoid use across healthcare professionals, patients and their families underpin market development. Familiarity with the product formulation itself drives adoption. Not only are most patients familiar with a capsule, but many will also see other benefits of this formulation. We are thrilled to see this product come to fruition in the UK and we are grateful to our partners helping us achieve this goal. This is the first milestone for us in our pipeline of innovative formulations we aim to bring to the UK and EU markets.”

Columbia Care’s partners in the UK are IPS Pharma, a leading pharmaceutical manufacturer licensed by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), who manufacture Columbia Care’s proprietary product formulations under the highest standards, and Grow Pharma, Columbia Care’s market access partner. Any interested parties can obtain further details from IPS Pharma and Grow Pharma. For more information on the UK medical cannabis program, visit The Centre for Medicinal Cannabis at https://thecmcuk.org/.

About Columbia Care
Columbia Care is one of the largest and most experienced cultivators, manufacturers and providers of medical and adult use cannabis products and related services with licenses in 18 U.S. jurisdictions and the EU. Columbia Care operates 114 facilitiesⁱ including 87 dispensaries and 27 cultivation and manufacturing facilities. Columbia Care is one of the original providers of medical cannabis in the United States, and continues to deliver an industry-leading, patient-centered medicinal cannabis operation that has quickly expanded into the adult use market as a premier operator. The company currently offers products spanning flower, edibles, oils, capsules and tablets, and manufactures popular brands including Seed & Stain, Amber and Platinum Label CBD. With more than four million sales transactions since its inception in 2012, Columbia Care is known for setting the standard for compassion, professionalism, quality, care, and innovation in the rapidly expanding cannabis industry. For more information on Columbia Care, please visit www.col-care.com.

Caution Concerning Forward-Looking Statements
This press release contains certain statements that constitute forward-looking information within the meaning of applicable securities laws and reflect the Company’s current expectations regarding future events. The Company has made assumptions with regard to its ability to execute on brand and product initiatives, which although considered reasonable by the Company, may prove to be incorrect and are subject to known and unknown risks and uncertainties that may cause actual results, performance or achievements of the Company to be materially different from those expressed or implied by any forward-looking information. Securityholders should review the risk factors discussed under “Risk Factors” in Columbia Care’s Annual Information Form dated March 31, 2021, filed with the applicable Canadian securities regulatory authorities on SEDAR at www.sedar.com and described from time to time in documents filed by the Company with Canadian securities regulatory authorities.

ⁱ Pro forma facilities either open or under development

View source version on businesswire.com: https://www.businesswire.com/news/home/20210415005328/en/

Investor Contact
Lee Ann Evans
Investor Relations
+1.212.271.0915
[email protected]

Media Contact
Lindsay Wilson
Columbia Care
+1.978.662.2038
[email protected]

UK Contact
Hari Guliani
Columbia Care International
[email protected]

Source: Columbia Care Inc.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

<!– Click –> <!– –>